Efficacy and tolerability of dronedarone for patients with atrial fibrillation by Teme, Tonye & Goldberger, Jeffrey J.
ORIGINAL ARTICLE
Cardiology Journal 
2013, Vol. 20, No. 5, pp. 486–490 
DOI: 10.5603/CJ.2013.0133
Copyright © 2013 Via Medica
ISSN 1897–5593
486 www.cardiologyjournal.org
Address for correspondence: Jeffrey J. Goldberger, MD, MBA, Northwestern University Feinberg School of Medicine, 
Division of Cardiology, 251 East Huron, Feinberg Pavilion, Chicago, IL 60611, USA, tel: 312-926-2148, fax: 312-926-2707, 
e-maill: j-goldberger@northwestern.edu
Received: 05.12.2012 Accepted: 10.01.2013
Efficacy and tolerability of dronedarone  
for patients with atrial fibrillation
Tonye Teme, Jeffrey J. Goldberger
Division of Cardiology, Department of Medicine, Feinberg School of Medicine,  
Northwestern University, Chicago, USA
Abstract
Background: Dronedarone is a new antiarrhythmic drug used in the treatment of atrial 
fibrillation (AF). We investigate its efficacy and tolerability in clinical practice.
Methods: We identified 208 patients treated with dronedarone for AF at the Northwestern 
outpatient practice. Charts were reviewed for clinical efficacy and reasons for discontinuation 
of the drug.
Results: The average age was 65.2 ± 10.8 years, 37% females. Paroxysmal, persistent and 
permanent AF were noted in 46.2%, 51.9%, and 1.9%, respectively. Average ejection fraction 
was 56.3 ± 9.1%, 12.8% had a history of congestive heart failure, and 10.3% had valvular 
heart disease. Dronedarone was discontinued in 25 patients after curative catheter or surgical 
ablation procedure. Of the remaining 183 patients, dronedarone was discontinued in 48.6% 
after a mean duration of 6.2 ± 6.3 months because of inefficacy (26.2%), side effects (6%), 
and other reasons (16.4%). For those remaining on dronedarone (n = 94), after a mean of  
11.6 ± 6.6 months, clinical efficacy (resolution of or patient-reported improvement in symptoms)  
was noted in 45.4% patients. On dronedarone therapy, 57.4% had no AF on follow-up (overall 
efficacy of 29.5%). To evaluate efficacy, ECG only or long-term monitoring were performed 
in 62.7% and 37.3%, respectively, and found no AF in 69.2 and 48.4%, respectively. There 
were 3 deaths and 2 transient ischemic attacks (TIA) off dronedarone vs. 1 death, 1 TIA and  
2 strokes on dronedarone. 
Conclusions: Dronedarone has a significant discontinuation rate due to both inefficacy and 
side effects in clinical practice. Nevertheless, it has moderate clinical efficacy and tolerability in 
an outpatient population of patients with AF. (Cardiol J 2013; 20, 5: 486–490)
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Introduction
Atrial fibrillation (AF) is a common arrhythmia 
[1] with significant morbidity and mortality [2]. 
Although management by rate or rhythm control are 
equally effective therapies in the management of AF 
[3–5] maintaining sinus rhythm may be beneficial in 
patients with symptoms or with other comorbidities 
[6]. Multiple antiarrhythmic drugs are available 
for use to prevent recurrent AF but are limited by 
modest efficacy and potentially serious side effects 
or toxicity [7, 8]. Amiodarone has relatively high ef-
ficacy [9] but also has significant risks of pulmonary, 
thyroid and hepatic toxicity [10–12]. 
Dronedarone, a non-iodinated benzofuran 
derivative of amiodarone [13, 14], was designed to 
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have a shorter half-life, lower tissue accumulation 
and less toxicity when compared to amiodarone. 
Prior prospective studies have shown low efficacy, 
with AF recurrence rates of approximately 63–65% 
over 6–12 months [15–17] and a side effect profile 
that is more favorable than amiodarone [17–19]. 
However, studies such as ANDROMEDA [20] and 
more recently, the PALLAS [21] trials revealed 
serious adverse effects when used in the setting 
of severe heart failure and permanent AF with an 
increase in mortality. There are no studies on the 
efficacy and side effects of dronedarone in clinical 
practice, outside the setting of a clinical trial. We 
report the efficacy and tolerability of dronedarone 
in patients with AF or atrial flutter (AFL) at a single 
academic institution.
Methods
Patients
From the Northwestern Electronic Data Wa-
rehouse, we identified 252 patients who were 
reported to have been prescribed dronedarone at 
the Northwestern outpatient practice. We exclu-
ded 35 patients for inaccurate medication listing; 
one patient had the drug only very briefly during 
a hospitalization; 2 patients were on dronedarone 
for ventricular tachycardia; 2 patients were treated 
with dronedarone empirically post-heart transplant 
and it was discontinued shortly thereafter; 4 pa-
tients were excluded for technical reasons. Thus, 
we report on the 208 patients who had dronedarone 
initiated for treatment of AF and/or AFL. 
The study was approved by the Northwestern 
University Institutional Review Board.
Study design
Each chart was reviewed for demographic data 
and prior medical history, type of AF and prior an-
tiarrhythmic agents and interventions. The type of 
AF was classified as paroxysmal: self-terminating 
episodes of AF for up to 7 days; persistent: AF 
lasting more than 7 days and usually requiring some 
kind of antiarrhythmic therapy or intervention to 
restore sinus rhythm; and permanent: persistent 
AF lasting more than 1 year or failure to restore 
sinus rhythm despite multiple antiarrhythmic 
therapies. Specific treatment parameters that were 
collected include clinical efficacy, and reasons for 
discontinuation of drug. Recurrence of AF, type of 
monitoring, all-cause mortality, stroke, and tran-
sient ischemic attack (TIA) were assessed during 
follow-up. 
Clinical efficacy included resolution of or 
patient-reported improvement in symptoms of 
palpitations, exercise intolerance, or dyspnea. 
Reasons for discontinuation were: inefficacy, side 
effects, curative procedures (surgical or catheter 
ablation), and other. Drug inefficacy was specified 
as discontinuation of dronedarone due to recurrent 
AF or symptoms/side effects warranting a change 
in therapy. The most important reason for discon-
tinuation was documented if a subject had more 
than one reason for discontinuation. Echocardio-
gram reports were reviewed for evidence of left 
atrial enlargement, left ventricular hypertrophy, 
aortic or mitral valve disease, and left ventricular 
ejection fraction (LVEF). Valvular disease (aortic 
insufficiency, aortic regurgitation, mitral stenosis 
or mitral regurgitation) was considered significant 
if it was reported to be moderate or severe. Renal 
disease was considered present if the recorded 
glomerular filtration rate was less than 60 mL/min. 
Information on stroke and TIA were obtained 
through chart review and information on mortality 
was obtained from the social security death index. 
Data analysis 
Categorical variables are expressed as absolu-
te numbers and percentages; quantitative variables 
are expressed as mean ± standard deviation (SD). 
Proportions were compared using two-proportion 
Z-test and continuous variables compared using 
T-test. A p < 0.05 was considered significant. 
Results
Dronedarone therapy and discontinuation
The clinical characteristics of the 208 patients 
treated with dronedarone are shown in Table 1. 
There were 131 (63%) men and 77 (37%) wo-
men with an average age of 65.2 ± 10.8 years. 
Prior stroke was present in 5 (2.4%) patients, 
36 (17.3%) patients had known obstructive coronary 
artery disease, and 7 (3.4%) had prior myocar-
dial infarction. Paroxysmal AF was present in 
96 (46.2%) patients, 108 (51.9%) had persistent AF, 
and 4 (1.9%) had permanent AF. Dronedarone was 
started primarily for AFL in only 4 (1.9%) patients. 
The average LVEF was 56.3 ± 9.1%. Congestive 
heart failure was present in 25 (12.8%) patients and 
20 (10.3%) had valvular heart disease. 
In 25 patients, dronedarone was discontinued 
because the patient had undergone a curative 
catheter or surgical ablation procedure (i.e. a plan-
ned discontinuation); these patients are exclu-
ded from further analysis. Out of the remaining 
183 patients, dronedarone was discontinued in 
89 (48.6%) patients after a mean treatment period of 
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Table 1. Patient characteristics.
  Total  
(n = 208)
On dronedarone 
(n = 94)
Dronedarone 
discontinued  
(n = 89)
P
Age [years] 65.2 ± 10.8 66 ± 10.1 66.3 ± 11.8
Caucasian 80.8% 74.5% 86.5% 0.04
Gender (male) 63.0% 64.9 55.1 0.17
Body mass index [kg/m2] 29.4 ± 6.0 29.5 ± 6.0 29.0 ± 6.1
Systolic blood pressure [mm Hg] 121.5 ± 16.4 122 ± 15.1 120.3 ± 17.2
Diastolic blood pressure [mm Hg] 72.2 ± 11.0 72.7 ± 9.7 70.2 ± 11.8
Current smoker 2.9% 3.2% 3.4%
Hypertension 55.3% 59.6% 55.1%
Diabetes mellitus 13.0% 10.6% 12.4%
Hyperlipidemia 66.3% 67.0% 62.9%
Renal disease 26.9% 25.5% 31.5%
History of stroke 2.4% 2.1% 2.2%
Prior myocardial infarction 3.4% 3.2% 4.5%
Coronary artery disease 17.3% 13.8% 20.2%
Type of atrial fibrillation:     
Paroxysmal 46.2% 53.2% 36.0% 0.02
Persistent 51.9% 46.8% 59.6% 0.08
Permanent 1.9% 0% 4.5% 0.04
CHADS II (median) 1 1 1
Left ventricular hypertrophy 8.2% 11.5% 6.0%
Left atrial enlargement 39.2% 43.7% 38.6%
Left ventricular ejection fraction [%] 56.3 ± 9.1 56.2 ± 8.6 56.3 ± 10.1
Congestive heart failure 12.8% 10.2% 16.7%
Valvular disease 10.3% 11.5% 9.6%
Hypothyroidism 20.3% 16.0% 24.7%
Chronic obstructive pulmonary disease 6.3% 5.3% 9.0%
Concomitant cardiovascular therapy:
Beta-blocker 61.5% 66.0% 58.4%
Calcium channel blocker 15.9% 13.8% 21.3%
Digoxin, 5.8% 2.1% 10.1% 0.02
ACE/ARB 36.5% 38.3% 41.6%
Statin 55.3% 57.4% 49.4%
Anticoagulation 95.2% 96.8% 93.3%
Prior antiarrhythmics: 53.4% 55.3% 50.6%
Amiodarone 30.3% 29.8% 31.5%
Sotalol 15.4% 16.0% 15.7%
Flecainide 5.8% 5.3% 6.7%
Propafenone 12.0% 14.9% 4.5% 0.01
Dofetilide 8.7% 3.2% 13.5% 0.01
Prior intervention: 46.6% 46.8% 47.2%
Cardioversion 30.3% 28.7% 29.2%
Catheter ablation 18.8% 23.4% 12.4% 0.05
Maze procedure 5.8% 5.3% 7.9%
ACE — angiotensin converting enzyme; ARB — angiotensin receptor blocker
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6.2 ± 6.3 months (range 5 days to 23.6 months). 
Discontinuation was due to inefficacy in 48 (26.2%) 
patients. Side effects resulting in discontinuation 
were reported in 11 (6%) patients and included 
gastrointestinal complaints (n = 5), rash (n = 1), 
fatigue (n = 3), weight gain (n = 1) and dizziness 
(n = 1). Other reported reasons for discontinu-
ation were observed in 30 (16.4%) patients and 
included following successful cardioversion to 
sinus rhythm (n = 1), permanent AF (n = 4), cost 
(n = 2), self-discontinuation (n = 3), bradycardia 
(n = 2), heart failure, renal and pulmonary function 
test abnormalities, pauses and junctional rhythm. 
Follow-up liver function tests were obtained in 
102 patients. Liver enzymes were elevated to 
> 2 times the upper limit of normal in 6 patients 
but was the sole reason for discontinuation in 
2 patients. There was no severe hepatotoxicity. 
Table 1 compares patient characteristics be-
tween those who remained on dronedarone and 
those in whom dronedarone was discontinued. We 
observed differences in race (74.5% Caucasians 
vs. 86.5%, p = 0.04), paroxysmal AF (53.2% vs. 
36.0%, p = 0.02), permanent AF (0% vs. 4.5%, 
p = 0.04), digoxin use (2.1% vs. 10.1%, p = 0.02), 
prior propafenone use (14.9% vs. 4.5%, p = 0.02) 
prior dofetilide use (3.2% vs. 13.5%, p = 0.01), and 
prior catheter ablation (23.4% vs. 12.4%, p = 0.05).
Follow-up
Ninety-four (51.4%) patients remained on 
dronedarone for a period of 11.6 ± 6.6 months. 
Of this group, 70 (74.5%) were concurrently on 
rate control medications (beta-blockers, calcium 
channel blockers, digoxin) and 36 (38.3%) had 
undergone other non-pharmacological interven-
tions (24.5% had direct current cardioversion, 
16.0% catheter ablation, and 3.2% surgery/maze 
procedure). Clinical efficacy was noted in 83 of 
these patients for a clinical efficacy rate of 45.4% 
(83/183). On dronedarone therapy, 57.4% had no 
AF documented on follow-up, for an overall efficacy 
of 29.5% (54/183). Of those with clinical efficacy, 
ECG monitoring alone was performed in 62.7% 
(n = 52) and identified no AF in 69.2% (n = 36). 
In contrast, long-term ambulatory monitoring was 
performed in 37.3% (n = 31) and identified no AF 
in 48.4% (n = 15). 
During the follow-up period, death occurred 
in 1 patient (subdural hematoma from a fall), stroke 
in 2 patients, and TIA in 1 patient while on drone-
darone therapy. Among those patients no longer 
on dronedarone, there were 3 deaths (2 due to 
malignancy and 1 of unknown causes) and 2 TIAs.
Discussion
Our results show that dronedarone is a mo-
derately effective drug in clinical practice for the 
treatment of AF. However, its use is limited by 
a fairly high discontinuation rate in approximately 
half the patients treated with this medication in cli-
nical practice. Overall efficacy rates, approximately 
30% to 45%, are similar to other antiarrhythmic 
drugs used to treat AF [7, 9, 22], but less effica-
cious than amiodarone [9, 17]. No major toxicity 
was identified in this series. Thus, dronedarone 
appears to be an effective drug in the therapeutic 
armamentarium for AF.
Prior prospective trials of dronedarone thera-
py have shown efficacy rates of 35% to 36% after 
a follow-up duration of 6 to 12 months [15–17]. 
In these studies, drug discontinuation due to side 
effects was reported in only 4–10% of patients. 
Touboul et al. [15] in the Dronedarone for preven-
tion of Atrial Fibrillation study (DAFNE) reported 
a 10.8% rate of discontinuation due to adverse side 
effects. Other reports have shown discontinuation 
rates due to side effects up to 13% [21, 23]. In the 
present study, a 6% discontinuation rate for side 
effects was noted. However, in the practice-based 
setting of this study, there was a substantial di-
scontinuation rate for multiple reasons aside from 
side effects. The reported efficacy rates in this 
study therefore likely represent a lower bound or 
underestimate of the efficacy of dronedarone. Yet, 
the efficacy compares favorably to those previously 
reported. 
The type of monitoring dictated how much AF 
was found on follow-up. A higher incidence of AF is 
expected with the use of long-term monitoring [24]. 
Prior studies [15–17] used predominantly ECG ba-
sed monitoring, often with regular transtelephonic 
transmissions of routine and symptomatic ECGs. In 
the current study, almost 40% of the dronedarone 
treated patients had long-term monitoring which 
will identify more AF. Importantly, while absence 
of AF is a major primary endpoint for AF therapy, 
symptomatic improvement is also a valid goal to 
achieve in the highly symptomatic patient. This 
highlights a potential disparity between clinical 
use and clinical trial efficacy endpoints. 
In theory, dronedarone is supposed to have 
limited hepatotoxicty compared to amiodarone 
[25]. Although prior studies have not shown any 
difference compared to amiodarone [17], they are 
limited due to the relatively short follow-up. The 
same findings are true when compared to placebo 
[16, 23]. However, there have been a few recent 
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case reports of elevated liver enzymes on drone-
darone with both hepatocellular and cholestatic 
liver injury [26]. In this study, a small number of 
patients with normal baseline liver function had 
a 2 to 3-fold increase in liver function tests, but 
there was no severe hepatotoxicity. 
Increased mortality from dronedarone has 
been observed in patients with advanced or de-
compensated heart failure (ANDROMEDA study, 
n = 310 treated with dronedarone) [20] and in 
patients with permanent AF (PALLAS study, 
n = 1619 treated with dronedarone) [21] after 
a short median duration of 2 and 3 months of the-
rapy, respectively. The ANDROMEDA study most 
likely influenced our sample population while the 
PALLAS study contributed to the discontinuation 
of the drug in a small number of patients. Most 
patients in the current report did not meet the 
criteria for these studies. Although the sample size 
is relatively small, there were no major adverse 
events related to the use of dronedarone in this 
clinical population. The 4 deaths (1 on dronedarone 
and 3 off dronedarone) that occurred in this study 
were not likely related to dronedarone use.
Conclusions
In conclusion, dronedarone is a non-iodinated 
benzofuran derivative of amiodarone [13, 14] 
thought to have better tolerability compared to 
amiodarone [17]. Our experience suggests that 
dronedarone has a significant discontinuation rate 
due to inefficacy, side effects, and other reasons 
in clinical practice. Nevertheless, it has moderate 
clinical efficacy and tolerability in an outpatient 
population of patients with non-permanent AF. 
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